Isis Pharmaceuticals Inc. advanced another candidate from its rare drug portfolio into phase III development, initiating a pivotal study of the antisense drug ISIS-SMNRx in infants with spinal muscular atrophy (SMA), the most common genetic cause of infant mortality.